Alnylam Pharmaceuticals, Inc. ALNY
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 2,200.08% | 397.25% | 365.92% | 239.71% | 135.65% |
| Total Depreciation and Amortization | -1.57% | -3.08% | -4.78% | -1.79% | 139.68% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -340.90% | 30.66% | 26.69% | 22.78% | 36.67% |
| Change in Net Operating Assets | 5.95% | -142.95% | -77.92% | -133.07% | -917.43% |
| Cash from Operations | 325.99% | 2,168.59% | 1,502.54% | 5,753.33% | 274.30% |
| Capital Expenditure | -236.27% | -151.57% | -136.37% | -71.24% | -9.90% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -226.49% | 324.85% | 288.70% | 699.57% | 276.11% |
| Cash from Investing | -275.45% | 167.65% | 360.14% | 473.44% | 238.08% |
| Total Debt Issued | -100.11% | -- | -- | -- | -- |
| Total Debt Repaid | 95.42% | -- | -- | -- | -- |
| Issuance of Common Stock | -57.53% | -39.56% | -34.50% | -17.47% | -17.80% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 506.01% | 433.36% | 442.06% | 622.10% | -430.25% |
| Cash from Financing | 143.57% | -225.36% | -190.38% | -185.33% | -187.75% |
| Foreign Exchange rate Adjustments | -170.48% | -140.97% | 57.69% | 329.25% | 80.73% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -32.61% | 310.33% | 104.48% | 348.83% | 480.05% |